PDF(Pubmed)
Abstract：
Heart failure (HF) is a life-threatening disorder and is treated by drug therapies and surgical interventions such as heart transplantation and left ventricular assist device (LVAD). However, these treatments can lack effectiveness in the long term and are associated with issues such as donor shortage in heart transplantation, and infection, stroke, or gastrointestinal bleeding in LVADs. Therefore, alternative therapeutic strategies are still needed. In this respect, stem cell therapy has been introduced for the treatment of HF and numerous preclinical and clinical studies are employing a range of stem cell varieties. These stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), have been shown to improve cardiac function and attenuate left ventricular remodeling. IPSCs, which have a capacity for unlimited proliferation and differentiation into cardiomyocytes, are a promising cell source for myocardial regeneration therapy. In this review, we discuss the following topics: (1) what are iPSCs; (2) the limitations and solutions for the translation of iPSC-CMs practically; and (3) the current therapeutic clinical trials.
摘要：
心力衰竭（HF）是一种危及生命的疾病，可通过药物治疗和外科手术如心脏移植和左心室辅助装置（LVAD）进行治疗。然而,从长远来看，这些治疗方法可能缺乏有效性，并且与心脏移植中供体短缺等问题有关，和感染，中风,或LVAD的胃肠道出血。因此,仍然需要替代治疗策略.在这方面,干细胞疗法已被引入用于治疗HF，许多临床前和临床研究正在采用一系列干细胞品种。这些干细胞,如胚胎干细胞（ESCs）和诱导多能干细胞（iPSCs），已被证明可以改善心脏功能并减轻左心室重塑。IPSC,具有无限增殖和分化为心肌细胞的能力，是心肌再生治疗的有前途的细胞来源。在这次审查中,我们讨论了以下主题:(1)什么是iPSCs;(2)iPSC-CM翻译的局限性和解决方案;(3)当前的治疗性临床试验.
